Sanofi

SAN
87,89
-0,95 (-1,07%)
29 Feb 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: Euronext
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
24/2/202415:51GLOBECommuniqué : Résultats de phase II montrent que le..
23/2/202418:45GLOBECommuniqué de presse : Dépôt du Document d’Enregistrement..
23/2/202407:00GLOBEPress Release: Dupixent® sBLA accepted for FDA Priority..
22/2/202419:02GLOBECommuniqué de presse : Le Conseil d’administration de Sanofi..
20/2/202423:40GLOBESanofi: Information concerning the total number of voting..
16/2/202407:00GLOBEPress Release: Japan first in the world to approve Dupixent®..
15/2/202414:00GLOBECommuniqué de presse : Des données de phase II publiées dans..
05/2/202408:00GLOBECommuniqué de presse : Entraide, conditions de travail..
01/2/202407:30GLOBECommuniqué de presse : François-Xavier Roger nommé Directeur..
25/1/202420:30GLOBECommuniqué de presse : Dupixent® : premier et seul..
23/1/202412:05DJNSanofi to Buy Assets From Inhibrx in Deal Valued at Up to..
23/1/202407:30GLOBECommuniqué de presse : Sanofi va acquérir Inhibrx, Inc. et..
17/1/202422:57GLOBESanofi: Information concerning the total number of voting..
09/1/202408:14DJNSanofi Names Brian Foard Head of Specialty-Care Unit
09/1/202407:30GLOBECommuniqué de presse : Brian Foard est nommé Responsable de..
21/12/202308:25DJNSanofi Ends Drug Program After Late-Stage Trial in Lung..
21/12/202307:30GLOBEPress Release: Sanofi announces end of program evaluating..
19/12/202313:28DJNInnate Pharma Shares Rise after Sanofi Exercises Licensing..
18/12/202321:59GLOBESanofi: Information concerning the total number of voting..
15/12/202307:30GLOBECommuniqué de presse : Mise en ligne du document «Q4 2023..
15/12/202307:00GLOBECommuniqué de presse : L’EMA a rendu un avis favorable pour..
11/12/202323:18DJNSanofi Terminates Agreement with Maze Therapeutics Following..
11/12/202322:08GLOBEPress Release: Statement on FTC challenge to proposed..
11/12/202307:50DJNSanofi Sees Improvement in Trial Results of Cancer Drug..
11/12/202301:30GLOBECP : Sarclisa® (isatuximab) plus KRd améliore..
07/12/202308:34DJNSanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage..
07/12/202308:20DJNSanofi Sees Annual Sales From New Pharma Assets Above $10.8..
07/12/202307:35GLOBECP : L’essai de phase III consacré au Sarclisa® (isatuximab)..
07/12/202303:30GLOBECommuniqué de presse : Sanofi sur la voie du leadership..
06/12/202314:20DJNTrending: Merck's Multiple Sclerosis Drug Misses..
06/12/202311:14DJNMerck Shares Slump After Multiple Sclerosis Drug Fails in..
30/11/202315:23DJNTeva Closes Collaboration Deal With Sanofi on IBD Treatment
27/11/202316:31DJNTrending: Sanofi's Notus Trial Meets Primary Endpoint
27/11/202308:40DJNSanofi Says Notus Phase 3 Trial of Dupixent Met Primary..
27/11/202307:30GLOBEDupixent® (dupilumab) Significantly Reduced COPD..
23/11/202318:00GLOBESanofi: Information concerning the total number of voting..
07/11/202314:56DJNSanofi Under Preliminary Probe in France Over Possible..
30/10/202313:14DJNMeiraGTx Gets $30 Million Investment From Sanofi
27/10/202317:47DJNSanofi Down Over 19%, on Pace for Record Percent Decrease --..
27/10/202310:43DJNSanofi Shares Tumble After Warning of Profit Hit From..
27/10/202308:54DJNSanofi Backs Guidance After Earnings, Sales Miss Views
27/10/202308:35DJNSanofi Plans to Split Consumer-Healthcare, Pharma Businesses..
27/10/202308:07DJNSanofi Plans to Spin Off Consumer-Healthcare Business
27/10/202307:31GLOBECommuniqué de presse : Un troisième trimestre solide, marqué..
27/10/202307:30GLOBECommuniqué de presse : Sanofi entame un nouveau chapitre de..
22/10/202321:00GLOBEPress Release: Dupixent® (dupilumab) Phase 3 Results show..
22/10/202320:59GLOBEDupixent® (dupilumab) Phase 3 Results Show Sustained..
19/10/202312:00GLOBECommuniqué de presse : Sanofi livre les premiers médicaments..
18/10/202311:40DJNSanofi Says Drug Shows Potential to Slow Diabetes in..
18/10/202310:45GLOBEPress Release: TZIELD® Phase 3 data presented at ISPAD shows..
Apertura: 88,61 Min: 87,88 Max: 89,23
Chiusura: 88,84

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

Assistenza utenti: +39 02 3045 3014 | support@advfn.it

ADVFN Network